Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells
Graft-versus-host disease (GVHD) is a frequent and severe complication of hematopoietic stem cell transplantation (HSC), and is responsible for significant early mortality despite prophylactic strategies developed in recent decades, Especially since it is resistant to first-line treatment.
The present diagnosis is difficult, non-specific and is based on the combination of an evocative clinical context (CSH allograft, time to appearance before J100, characteristic clinical manifestations), suggestive anatomo-pathological analysis (predominantly inflammatory infiltrate Lymphocyte, mucosal edema and presence of apoptotic bodies), and the exclusion of any differential diagnosis (in particular serology / negative viral PCR).
However, to date there is no molecular characterization of this manifestation, and therefore no specific treatment.
The nCounter® nanostring technology allows the rapid and simple analysis of the simultaneous expression of a group of genes (up to 800 on the same sample), from a very small amount of RNA, and from samples with difficulty Such as fabrics already fixed to formaldehyde and included in paraffin. It allows the detection of a "molecular signature" of the tissue analyzed.
No transcriptomic analysis has ever been performed on human tissues with GVHD.
研究概览
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
Picardie
-
Amiens、Picardie、法国、80054
- 招聘中
- CHU Amiens Picardie
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Person aged ≥ 18 years
- Patients who have received an HSC allograft since June 2012
- Having presented a suspicion of cutaneous or digestive GVHD before J100 post-allograft
- Of which the diagnosis was retained by the combination of clinical and histological criteria
- Or whose diagnosis has been reversed by histological analysis, for the reactive / inflammatory biopsies that serve as control
- The diagnosis of which was made between 01/01/2013 and 31/12/2015
- Survived at least 1 month to monitor clinical progress
Exclusion Criteria:
- Whose biopsy specimens were also the sites of a viral reactivation (EBV, CMV, HHV) that could mimic a GVHD
- Having survived less than 1 month after the diagnosis of GVHD
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Transcriptomic profile by analysis of the expression of the mRNAs of a determined panel of 800 genes regulating the immune response
大体时间：3 months
|
3 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.